We are thrilled to announce that RarePULSE® our innovative omnichannel service has officially received registered trademark status from the Intellectual Property Office (IPO). This designation affirms RarePULSE® as a trusted tool in the field of omnichannel listening, designed specifically to identify insights and trends within rare and underserved communities.
RarePULSE® utilizes advanced analytics to deliver precise, actionable insights into patient and stakeholder experiences, allowing our customers to make data-driven decisions that improve outcomes. With this registered trademark, RarePULSE® stands out as a unique and protected service in the social media listening space, ensuring clients receive reliable, high-quality insights they can depend on.
Sophie Schmitz, Managing Partner of Partners4Access commented: “Omnichannel listening is one of the most cost effective and efficient methods to better understand the patient populations, unmet needs and very importantly, champion patient-centricity. By providing access to authentic patient, caregiver and clinician voices and real-world insights, RarePULSE® can significantly enhance the effectiveness to manufacturers’ orphan drug and ATMP development efforts.”
Darren Callanan, Global Digital Lead of Partners4Access: “We are thrilled to see RarePulse® earn its trademark, solidifying its place as a premier tool for strategic insights in rare and specialty fields. With RarePulse®, our clients gain access to unbiased, real-time insights into patient and clinician perspectives, which can provide clarity to a range of activities such as trial design, understanding the disease burden, and treatment positioning. The unprompted approach to data gathering we take promotes unbiased input, and the speed with which we deliver findings—often within 10 days—enables clients to make timely, data-driven decisions. RarePulse® is reshaping how we understand and respond to patient, caregiver and clinician perceptions across the healthcare landscape.”
About Partners4Access
Partners4Access (P4A) is a global consultancy specializing in market access for orphan drugs, gene therapies, and other rare disease treatments. P4A’s expertise lies in navigating the unique challenges of launching and accessing innovative therapies, helping clients bring life-saving treatments to patients around the world. With a team of experienced professionals, P4A provides tailored solutions to optimize pricing, reimbursement, and market access strategies
For more information, please visit our website at www.partners4access.com
Contact:
Darren Callanan
Global Digital Lead
[email protected]
